Annual CFO
-$306.00 M
-$744.00 M-169.86%
31 December 2023
Summary:
Arcus Biosciences annual cash flow from operations is currently -$306.00 million, with the most recent change of -$744.00 million (-169.86%) on 31 December 2023. During the last 3 years, it has fallen by -$417.00 million (-375.68%). RCUS annual CFO is now -169.86% below its all-time high of $438.00 million, reached on 31 December 2022.RCUS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$26.00 M
+$120.00 M+127.66%
30 September 2024
Summary:
Arcus Biosciences quarterly cash flow from operations is currently $26.00 million, with the most recent change of +$120.00 million (+127.66%) on 30 September 2024. Over the past year, it has increased by +$89.00 million (+141.27%). RCUS quarterly CFO is now -96.02% below its all-time high of $654.00 million, reached on 31 March 2022.RCUS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$158.00 M
+$89.00 M+36.03%
30 September 2024
Summary:
Arcus Biosciences TTM cash flow from operations is currently -$158.00 million, with the most recent change of +$89.00 million (+36.03%) on 30 September 2024. Over the past year, it has increased by +$130.00 million (+45.14%). RCUS TTM CFO is now -133.38% below its all-time high of $473.31 million, reached on 30 June 2022.RCUS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RCUS Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -169.9% | +141.3% | +45.1% |
| 3 y3 years | -375.7% | +148.4% | +35.3% |
| 5 y5 years | -611.7% | +194.9% | -122.2% |
RCUS Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -169.9% | at low | -96.0% | +126.5% | -133.4% | +49.7% |
| 5 y | 5 years | -169.9% | at low | -96.0% | +126.5% | -133.4% | +49.7% |
| alltime | all time | -169.9% | at low | -96.0% | +126.5% | -133.4% | +49.7% |
Arcus Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $26.00 M(-127.7%) | -$158.00 M(-36.0%) |
| June 2024 | - | -$94.00 M(+4600.0%) | -$247.00 M(+17.6%) |
| Mar 2024 | - | -$2.00 M(-97.7%) | -$210.00 M(-31.4%) |
| Dec 2023 | -$306.00 M(-169.9%) | -$88.00 M(+39.7%) | -$306.00 M(+6.3%) |
| Sept 2023 | - | -$63.00 M(+10.5%) | -$288.00 M(-5.9%) |
| June 2023 | - | -$57.00 M(-41.8%) | -$306.00 M(-2.5%) |
| Mar 2023 | - | -$98.00 M(+40.0%) | -$314.00 M(-171.7%) |
| Dec 2022 | $438.00 M(-271.1%) | -$70.00 M(-13.6%) | $438.00 M(-1.8%) |
| Sept 2022 | - | -$81.00 M(+24.6%) | $446.07 M(-5.8%) |
| June 2022 | - | -$65.00 M(-109.9%) | $473.31 M(+1.9%) |
| Mar 2022 | - | $654.00 M(-1156.0%) | $464.32 M(-281.4%) |
| Dec 2021 | -$256.00 M(-330.6%) | -$61.93 M(+15.2%) | -$256.00 M(+4.9%) |
| Sept 2021 | - | -$53.76 M(-27.4%) | -$244.12 M(-1042.4%) |
| June 2021 | - | -$74.00 M(+11.6%) | $25.90 M(-65.9%) |
| Mar 2021 | - | -$66.32 M(+32.5%) | $75.96 M(-31.6%) |
| Dec 2020 | $111.00 M | -$50.05 M(-123.1%) | $111.00 M(-26.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $216.26 M(-1003.4%) | $151.58 M(-264.6%) |
| June 2020 | - | -$23.94 M(-23.5%) | -$92.08 M(+4.8%) |
| Mar 2020 | - | -$31.28 M(+230.2%) | -$87.90 M(+19.7%) |
| Dec 2019 | -$73.46 M(+70.9%) | -$9.47 M(-65.4%) | -$73.46 M(+3.3%) |
| Sept 2019 | - | -$27.40 M(+38.7%) | -$71.10 M(+28.2%) |
| June 2019 | - | -$19.75 M(+17.3%) | -$55.46 M(+19.1%) |
| Mar 2019 | - | -$16.84 M(+136.9%) | -$46.59 M(+8.4%) |
| Dec 2018 | -$43.00 M(+71.6%) | -$7.11 M(-39.6%) | -$43.00 M(+111.8%) |
| Sept 2018 | - | -$11.77 M(+8.2%) | -$20.30 M(-38.0%) |
| June 2018 | - | -$10.88 M(-17.9%) | -$32.77 M(+14.1%) |
| Mar 2018 | - | -$13.25 M(-185.0%) | -$28.71 M(+14.6%) |
| Dec 2017 | -$25.06 M(+93.6%) | $15.59 M(-164.3%) | -$25.06 M(-38.3%) |
| Sept 2017 | - | -$24.23 M(+255.6%) | -$40.65 M(+147.7%) |
| June 2017 | - | -$6.82 M(-29.0%) | -$16.41 M(+71.0%) |
| Mar 2017 | - | -$9.60 M | -$9.60 M |
| Dec 2016 | -$12.94 M | - | - |
FAQ
- What is Arcus Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Arcus Biosciences?
- What is Arcus Biosciences annual CFO year-on-year change?
- What is Arcus Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Arcus Biosciences?
- What is Arcus Biosciences quarterly CFO year-on-year change?
- What is Arcus Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Arcus Biosciences?
- What is Arcus Biosciences TTM CFO year-on-year change?
What is Arcus Biosciences annual cash flow from operations?
The current annual CFO of RCUS is -$306.00 M
What is the all time high annual CFO for Arcus Biosciences?
Arcus Biosciences all-time high annual cash flow from operations is $438.00 M
What is Arcus Biosciences annual CFO year-on-year change?
Over the past year, RCUS annual cash flow from operations has changed by -$744.00 M (-169.86%)
What is Arcus Biosciences quarterly cash flow from operations?
The current quarterly CFO of RCUS is $26.00 M
What is the all time high quarterly CFO for Arcus Biosciences?
Arcus Biosciences all-time high quarterly cash flow from operations is $654.00 M
What is Arcus Biosciences quarterly CFO year-on-year change?
Over the past year, RCUS quarterly cash flow from operations has changed by +$89.00 M (+141.27%)
What is Arcus Biosciences TTM cash flow from operations?
The current TTM CFO of RCUS is -$158.00 M
What is the all time high TTM CFO for Arcus Biosciences?
Arcus Biosciences all-time high TTM cash flow from operations is $473.31 M
What is Arcus Biosciences TTM CFO year-on-year change?
Over the past year, RCUS TTM cash flow from operations has changed by +$130.00 M (+45.14%)